Ivory D Hills

US Patent:

8293759, Oct 23, 2012

Filed:

Oct 29, 2007

Appl. No.:

12/447802

Inventors:

Shaun R. Stauffer - Schwenksville PA, US
Ivory D. Hills - Harleysville PA, US
Ashley Nomland - Sellersville PA, US

Assignee:

Merck, Sharp & Dohme, Corp. - Rahway NJ

International Classification:

C07D 471/10
C07D 471/20
A61K 31/438

US Classification:

514278, 546 20

Abstract:

The present invention is directed to spiropiperidine compounds of formula (I).

US Patent:

8492387, Jul 23, 2013

Filed:

Feb 18, 2009

Appl. No.:

12/919277

Inventors:

Ivory D. Hills - Harleysville PA, US
Craig A. Coburn - Royersford PA, US
Samuel L. Graham - Schwenksville PA, US
Keith P. Moore - Harleysville PA, US
Philippe G. Nantermet - Lansdale PA, US
Hemaka A. Rajapakse - Wyncote PA, US
Shawn J. Stachel - Perkasie PA, US
Hong Zhu - Lansdale PA, US

Assignee:

Merck, Sharp & Dohme, Corp. - Rahway NJ

International Classification:

A61K 31/506
A61K 31/42
A61K 31/4174
A61K 31/4178
A61K 31/4439
A61K 31/422
C07D 233/88
C07D 403/10
C07D 403/06
C07D 413/10
C07D 401/10

US Classification:

514256, 514341, 514374, 514378, 514397, 514398, 544333, 5462714, 5462727, 548247, 5483144, 5483151, 5483265, 548 6

Abstract:

The present invention is directed to 2-aminoimidazole compounds of formula (I).

US Patent:

20090087376, Apr 2, 2009

Filed:

Jul 15, 2005

Appl. No.:

11/632328

Inventors:

Brian Bacskai - Charlestown MA, US
Bradley T. Hyman - Swampscott MA, US
William E. Klunk - Pittsburgh PA, US
Chester A. Mathis - Pittsburgh PA, US
Timothy Swager - Newton MA, US
Evgueni Nesterov - Cambridge LA, US
Ivory Hills - Harleysville PA, US

Assignee:

The General Hospital Corporation - Boston MA
Massachusetts Institute of Technology - Cambridge MA
University of Pittsburg of the Commonwealth System of Higher Education - Pittsburg PA

International Classification:

A61K 51/04
C07D 249/04
C07D 403/02
C07D 277/62
C07D 263/54
C07D 209/04
A61P 25/00
C07D 409/02
C07D 333/50
A61K 49/00
A61K 49/06

US Classification:

424 165, 548255, 544300, 548178, 548217, 548468, 549 59, 549 49, 424 91, 424 93

Abstract:

The present invention relates to the identification of compounds that are suitable for imaging amyloid deposits in living patients. The invention relates, in part, to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease. The present invention also relates to therapeutic uses for such compounds, as exemplified by compounds of the formula (1) in which Y is independently S, O, or N and m is 1, 2, or 3.

US Patent:

20110306626, Dec 15, 2011

Filed:

Dec 10, 2009

Appl. No.:

13/139610

Inventors:

Harold G. Selnick - Ambler PA, US
Michael R. Wood - Brentwood TN, US
Melody McWherter - Boyertown PA, US
Ivory D. Hills - Harleysville PA, US
Craig A. Stump - Pottstown PA, US

International Classification:

A61K 31/437
C07D 491/107
C07D 403/12
C07D 471/20
A61K 31/4184
A61P 9/12
A61K 31/444
A61P 25/06
A61P 25/00
A61P 29/00
A61P 25/08
C07D 471/10
A61K 31/4439

US Classification:

514278, 546 15, 5483011, 514387

Abstract:

The present invention is directed to imidazolinone derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

US Patent:

20120115885, May 10, 2012

Filed:

Jul 19, 2010

Appl. No.:

13/384946

Inventors:

Pablo De Leon - Philadelphia PA, US
Melissa Egbertson - Ambler PA, US
Ivory D. Hills - Harleysville PA, US
Adam Wayne Johnson - North Wales PA, US
Michelle Machacek - Brookline MA, US

International Classification:

A61K 31/4709
C07D 409/04
C07D 215/22
A61K 31/4704
A61P 25/18
C07D 401/12
A61P 25/22
A61P 25/00
A61P 25/16
C07D 409/14
A61K 31/506

US Classification:

514256, 546157, 514312, 544333

Abstract:

The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

US Patent:

20130053572, Feb 28, 2013

Filed:

Jan 19, 2011

Appl. No.:

13/574315

Inventors:

Steven L. Colletti - Princeton Junction NJ, US
Zhengwu James Deng - Eagleville PA, US
Matthew G. Stanton - Marlton NJ, US
Weimin Wang - Churchville PA, US
Ivory Hills - Deerfield MA, US

International Classification:

C07C 217/40
C07D 211/44
C07D 211/32
C07C 217/52
C07D 211/46
C07D 207/08
C07D 207/12

US Classification:

546242, 564504, 548570, 548574, 548543, 564 1, 548556, 546248

Abstract:

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that is susceptible to hydrolytic instability that may translate into reduced liver residence times and reduced hepatocellular toxicity. The present invention employs acetals and ketals to provide a low pH sensitive chemical handle for degradation.

US Patent:

20130090372, Apr 11, 2013

Filed:

May 31, 2011

Appl. No.:

13/701636

Inventors:

Brian W. Budzik - Perkiomenville PA, US
Steven L. Colletti - Princeton Junction NJ, US
Jennifer R. Davis - Richboro PA, US
Ivory D. Hills - Deerfield MA, US
Darla Danile Seifried - Lansdale PA, US
Matthew G. Stanton - Marlton NJ, US

International Classification:

C07C 217/46

US Classification:

514 44 A, 564504

Abstract:

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

US Patent:

20170050917, Feb 23, 2017

Filed:

Mar 22, 2016

Appl. No.:

15/077447

Inventors:

- Cambridge MA, US
Steven L. COLLETTI - Princeton Junction NJ, US
Jennifer R. DAVIS - Richboro PA, US
Ivory D. HILLS - Deerfield MA, US
Darla Danile SEIFRIED - Lansdale PA, US
Matthew G. STANTON - Marlton NJ, US

Assignee:

SIRNA THERAPEUTICS, INC. - Cambridge MA

International Classification:

C07C 217/46
C07C 217/44
C07D 317/28
C07D 295/084

Abstract:

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.